Compartir
array:23 [ "pii" => "S0121812323000695" "issn" => "01218123" "doi" => "10.1016/j.rcreu.2023.09.001" "estado" => "S300" "fechaPublicacion" => "2024-04-01" "aid" => "2075" "copyright" => "Asociación Colombiana de Reumatología" "copyrightAnyo" => "2023" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Rev Colomb Reumatol. 2024;31 Supl 1:S54-S66" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S0121812323000816" "issn" => "01218123" "doi" => "10.1016/j.rcreu.2023.08.005" "estado" => "S300" "fechaPublicacion" => "2024-04-01" "aid" => "2078" "copyright" => "Asociación Colombiana de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Rev Colomb Reumatol. 2024;31 Supl 1:S67-S73" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Measurement of health-related quality of life in patients with interstitial lung disease and autoimmune diseases" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S67" "paginaFinal" => "S73" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Medición de calidad de vida relacionada con la salud en pacientes con enfermedad pulmonar intersticial y enfermedades autoinmunes" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Claudia Mora, Alirio Rodrigo Bastidas Goyes, Lina Paola Fajardo Muriel, Cristian Felipe Rodríguez Yasno" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Claudia" "apellidos" => "Mora" ] 1 => array:2 [ "nombre" => "Alirio Rodrigo" "apellidos" => "Bastidas Goyes" ] 2 => array:2 [ "nombre" => "Lina Paola" "apellidos" => "Fajardo Muriel" ] 3 => array:2 [ "nombre" => "Cristian Felipe" "apellidos" => "Rodríguez Yasno" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0121812323000816?idApp=UINPBA00004N" "url" => "/01218123/00000031000000S1/v5_202405200140/S0121812323000816/v5_202405200140/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0121812323000671" "issn" => "01218123" "doi" => "10.1016/j.rcreu.2023.07.006" "estado" => "S300" "fechaPublicacion" => "2024-04-01" "aid" => "2074" "copyright" => "Asociación Colombiana de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Rev Colomb Reumatol. 2024;31 Supl 1:S45-S53" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review Article</span>" "titulo" => "Interstitial pneumonia with autoimmune features: Aiming to define, refine, and treat" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S45" "paginaFinal" => "S53" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Neumonía intersticial con características autoinmunes: definir, afinar y tratar" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 803 "Ancho" => 2167 "Tamanyo" => 169500 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">IPAF has unclear pathogenesis, prognosis, and optimal management. IPAF: idiopathic pneumonia with autoimmune features; UIP: usual interstitial pneumonia; ILD: interstitial lung disease; NSIP: non-specific interstitial pneumonia; OP: organizing pneumonia; LIP: lymphocytic interstitial pneumonia.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Elena K. Joerns, Jeffrey A. Sparks" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Elena K." "apellidos" => "Joerns" ] 1 => array:2 [ "nombre" => "Jeffrey A." "apellidos" => "Sparks" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0121812323000671?idApp=UINPBA00004N" "url" => "/01218123/00000031000000S1/v5_202405200140/S0121812323000671/v5_202405200140/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Systemic sclerosis and interstitial lung disease: From pathogenesis, to screening, diagnosis, and classification" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S54" "paginaFinal" => "S66" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Helena Codes, Aslihan Avanoglu Guler, Corrado Campochiaro, Marco Matucci Cerinic, Ivan Castellvi" "autores" => array:5 [ 0 => array:3 [ "nombre" => "Helena" "apellidos" => "Codes" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "Aslihan Avanoglu" "apellidos" => "Guler" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 2 => array:3 [ "nombre" => "Corrado" "apellidos" => "Campochiaro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "Marco Matucci" "apellidos" => "Cerinic" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 4 => array:4 [ "nombre" => "Ivan" "apellidos" => "Castellvi" "email" => array:1 [ 0 => "Castellvi@santpau.cat" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Department of Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Department of Internal Medicine, Division of Rheumatology, Gazi University Hospital, Ankara, Turkey" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author</span>." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Esclerosis sistémica y enfermedad pulmonar intersticial: de la patogenia al cribado, el diagnóstico y la clasificación" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 358 "Ancho" => 1005 "Tamanyo" => 72233 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">(A) NSIP with subpleural multifocal patchy ground-glass opacities (arrows); (B) subpleural dendriform ossification is also observed (arrows).</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Systemic sclerosis (SSc) is an autoimmune connective tissue disorder which can progress with multiple life-threatening organ involvement including interstitial lung disease (ILD). To date, three pathogenic pathways for the development of SSc have been implicated, including immune dysregulation, vasculopathy, and progressive fibrosis. ILD is one of the most common manifestations of SSc and a primary contributor to SSc-related deaths, followed by pulmonary arterial hypertension and cardiac causes.<a class="elsevierStyleCrossRefs" href="#bib0715"><span class="elsevierStyleSup">1–3</span></a> The clinical presentations of SSc-related ILD (SSc-ILD) vary from asymptomatic with stable lung function to severe dyspnea and cough with progressive lung involvement.<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">4</span></a> Considering the complex nature and heterogenous clinical presentation of SSc-ILD, both proper assessment of patients for early diagnosis and management and better understanding of the disease pathogenesis are crucial for mitigating the detrimental consequences of SSc-ILD and development of better, and someday, curative treatments.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">The pathogenesis of SSc-related ILD</span><p id="par0010" class="elsevierStylePara elsevierViewall">Results of clinical and preclinical animal-based studies have revealed that SSc-ILD proceeds from various complex pathways which might be summarized in endothelial and epithelial lung injury. There is dysregulation of the immune system including innate and adaptive immune cells with an increase in pro-inflammatory and pro-fibrotic cytokines, eventually resulting in fibrosis with exaggerated deposition of extracellular matrix (ECM).<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">5</span></a> However, there are still major areas of uncertainty regarding the pathogenesis of SSc-ILD.</p><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">The role of lung/tissue injury in SSc-ILD</span><p id="par0015" class="elsevierStylePara elsevierViewall">Repetitive and sustained injury of alveolar endothelial and epithelial cells is believed to be the initial step for the development of ILD-SSc.<a class="elsevierStyleCrossRefs" href="#bib0740"><span class="elsevierStyleSup">6,7</span></a> Thrombin, a procoagulant factor, is released after tissue and vascular injury. Bronchoalveolar fluid (BAL) from patients with SSc who have pulmonary fibrosis demonstrates a remarkable increase in thrombin activity with associated mitogenic activity of thrombin on lung fibroblasts that may be related to pulmonary fibrosis.<a class="elsevierStyleCrossRef" href="#bib0750"><span class="elsevierStyleSup">8</span></a> As well, thrombin promotes the differentiation of lung fibroblasts into myofibroblasts, which is the cornerstone of the fibrotic process.<a class="elsevierStyleCrossRef" href="#bib0755"><span class="elsevierStyleSup">9</span></a> The preclinical studies assessing the inhibition of thrombin have demonstrated that dabigatran, a direct thrombin inhibitor, reduces the myofibroblast differentiation of lung fibroblasts and pulmonary fibrosis.<a class="elsevierStyleCrossRefs" href="#bib0760"><span class="elsevierStyleSup">10,11</span></a> However, at the clinical level, a study evaluating the tolerability and safety of dabigatran in patients with SSc-ILD failed to show an effect of dabigatran on pulmonary function tests (PFTs).<a class="elsevierStyleCrossRef" href="#bib0770"><span class="elsevierStyleSup">12</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">Another possible mediator released after lung injury is endothelin-1 (ET-1) which is a strong vasoconstrictor and is secreted by endothelial cells, epithelial cells, and alveolar macrophages. ET-1 has pro-inflammatory and pro-fibrotic effects by activating the neutrophil aggregations, cytokine production and inducing fibroblasts, and promoting endothelial-mesenchymal transition (EndoMT).<a class="elsevierStyleCrossRefs" href="#bib0775"><span class="elsevierStyleSup">13–15</span></a> The pathologic assessment of lung tissue from patients with SSc-ILD has revealed a marked increase in expression of ET-1 and its receptors.<a class="elsevierStyleCrossRef" href="#bib0790"><span class="elsevierStyleSup">16</span></a> Furthermore, serum ET-1 level has been found to be significantly increased in serum and BAL from patients with SSc-ILD in previous studies.<a class="elsevierStyleCrossRefs" href="#bib0795"><span class="elsevierStyleSup">17–19</span></a> Moreover, the evaluation of patients with SSc with nailfold video capillaroscopy has elucidated that peripheric microvascular abnormalities reflecting the endothelial damage are related to ILD, supporting the role of microvascular injury in the pathogenesis of SSc-ILD.<a class="elsevierStyleCrossRef" href="#bib0810"><span class="elsevierStyleSup">20</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Alveolar epithelial cells (AECs) divide into two cell subsets. Type I AECs comprise the majority of the alveolar epithelial line, and type II AECs, which are proliferating cells with a high regeneration capacity and are responsible for production of surfactants.<a class="elsevierStyleCrossRefs" href="#bib0815"><span class="elsevierStyleSup">21,22</span></a> Apart from surfactants, type II AECs produce a mucin-like glycoprotein, called Krebs von den Lungen-6 (KL-6). The level of KL-6 increases with alveolar epithelial damage or cellular regeneration.<a class="elsevierStyleCrossRef" href="#bib0825"><span class="elsevierStyleSup">23</span></a> KL-6 induces lung fibroblast proliferation while inhibiting the apoptosis of fibroblasts.<a class="elsevierStyleCrossRef" href="#bib0830"><span class="elsevierStyleSup">24</span></a> The serum level of KL-6 is found to be markedly elevated in SSc-ILD and related to the severity of lung involvement.<a class="elsevierStyleCrossRefs" href="#bib0835"><span class="elsevierStyleSup">25,26</span></a> After epithelial alveolar injury, type II AECs start to proliferate and some undergo apoptosis while the remaining cells differentiate into type I AECs in normal repair. However, in pathologic conditions such as idiopathic pulmonary fibrosis or SSc-ILD, type II AECs have been implicated in fibrosis due to their capacity for endothelial-mesenchymal transition (EMT) through transforming-growth factor beta (TGF-β) signaling.<a class="elsevierStyleCrossRefs" href="#bib0820"><span class="elsevierStyleSup">22,27</span></a> Furthermore, alveolar macrophages and type II AECs are considered as a TGF-β secreting cells in SSc with fibrosing alveolitis.<a class="elsevierStyleCrossRef" href="#bib0850"><span class="elsevierStyleSup">28</span></a> Similar to AECs, lung endothelial cells can differentiate into fibroblasts in bleomycin-induced lung injury and fibrosis.<a class="elsevierStyleCrossRef" href="#bib0855"><span class="elsevierStyleSup">29</span></a> The immunohistopathological investigation of lung tissue has demonstrated the occurrence of EndoMT in SSc-ILD.<a class="elsevierStyleCrossRef" href="#bib0860"><span class="elsevierStyleSup">30</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">The role of inflammation and alteration of immune cells in SSc-ILD</span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Alveolitis-inflammation</span><p id="par0030" class="elsevierStylePara elsevierViewall">Alveolitis, the infiltration of alveoli with inflammatory and immune cells, is reflected in an increased percentage of neutrophils, lymphocytes or eosinophils in BAL.<a class="elsevierStyleCrossRef" href="#bib0865"><span class="elsevierStyleSup">31</span></a> The results of numerous studies revealed a prominent granulocytosis (neutrophilia and eosinophilia) in BAL from patients with SSc-ILD.<a class="elsevierStyleCrossRef" href="#bib0870"><span class="elsevierStyleSup">32</span></a> Moreover, significant neutrophilia on BAL is found in patients with SSc even with normal findings on computed tomography (CT) of the chest compared to healthy participants.<a class="elsevierStyleCrossRef" href="#bib0875"><span class="elsevierStyleSup">33</span></a> Histopathologic examination of the lung in patients with SSc at an early stage has shown interalveolar inflammation with a higher number of macrophages and infiltration of the interstitium with lymphocytes and plasma cells. As well, inflammation and fibrosis are found together which may support the role of inflammation in the fibrosis of SSc-ILD. Interestingly, occasional polymorphonuclear cells in alveolar space are detected in contrast to BAL findings.<a class="elsevierStyleCrossRef" href="#bib0880"><span class="elsevierStyleSup">34</span></a> In BAL or sera of patients with SSc-ILD, the levels of pro-inflammatory markers such as interleukin (IL)-6, IL-8, IL-4, monocyte chemoattractant protein-1 (MCP-1), leukotriene B4, and leukotriene E4 are increased.<a class="elsevierStyleCrossRefs" href="#bib0885"><span class="elsevierStyleSup">35–39</span></a> All these results strongly suggest that inflammation may play a pivotal role in the pathogenesis of SSc-ILD.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">T cells</span><p id="par0035" class="elsevierStylePara elsevierViewall">Activated specific adaptive immune cells including T helper (Th)2 cells, Th22 cells, Th17 cells, and B cells participate in the pathogenesis of SSc-ILD.<a class="elsevierStyleCrossRef" href="#bib0820"><span class="elsevierStyleSup">22</span></a> The differentiation toward Th2 cells, which have a profibrotic phenotype, has been observed in SSc. IL-4 and IL-13, mainly produced by Th2 cells, have profibrotic effects through the activation of fibroblast and promoting collagen synthesis via the TGF-β pathway.<a class="elsevierStyleCrossRef" href="#bib0910"><span class="elsevierStyleSup">40</span></a> Another important role of these cytokines is the activation of macrophages with the profibrotic phenotype (M2 polarization) which has been suggested to play a role in the fibrotic process in SSc.<a class="elsevierStyleCrossRef" href="#bib0915"><span class="elsevierStyleSup">41</span></a> The level of IL-4 is significantly higher in BAL and sera of patients with SSc-ILD.<a class="elsevierStyleCrossRefs" href="#bib0890"><span class="elsevierStyleSup">36,39</span></a> A recent study has demonstrated a significant association between IL-13 level and severity of ILD in SSc.<a class="elsevierStyleCrossRef" href="#bib0920"><span class="elsevierStyleSup">42</span></a> Moreover, the frequency of CD4<span class="elsevierStyleSup">+</span> T cells producing IL-22 is shown to be elevated in patients with SSc-ILD, and the level of serum IL-22 is positively correlated with the presence of ILD in SSc.<a class="elsevierStyleCrossRefs" href="#bib0925"><span class="elsevierStyleSup">43,44</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">Several studies have evaluated the role of regulatory T (Treg) cells in SSc. These cells are responsible for maintaining immune homeostasis and suppressing effector immune cells. Several studies have demonstrated a remarkable decline in circulating Treg cells in SSc, although a few studies have shown a significant increase in Treg cells.<a class="elsevierStyleCrossRef" href="#bib0935"><span class="elsevierStyleSup">45</span></a> A study with a small number of patients with SSc reported a significant increase in the ratio of Treg cells and Th17 cells in SSc compared to healthy controls.<a class="elsevierStyleCrossRef" href="#bib0940"><span class="elsevierStyleSup">46</span></a> This study also reported an elevated percentage of Treg cells in patients with high ILD scores on CT and in patients with decreased carbon monoxide diffusing capacity (DLCO).<a class="elsevierStyleCrossRef" href="#bib0940"><span class="elsevierStyleSup">46</span></a> Another recent study reported that patients with SSc-ILD have a higher number of Treg cells than healthy controls.<a class="elsevierStyleCrossRef" href="#bib0945"><span class="elsevierStyleSup">47</span></a> Moreover, the level of IL-35, secreted mainly by Treg cells, is found to be increased in patients with SSc who have 94% of the lung involved. The level of IL-35 is positively associated with Treg cells and high-resolution computerized tomography (HRCT) PFT lung scores.<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">48</span></a> These results might be explained by the diminished suppressive effect of Treg cells in SSc.<a class="elsevierStyleCrossRefs" href="#bib0955"><span class="elsevierStyleSup">49,50</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">IL-33 is released from stromal cells such as epithelial cells, endothelial cells, and fibroblasts after tissue injury or cell damage.<a class="elsevierStyleCrossRef" href="#bib0965"><span class="elsevierStyleSup">51</span></a> IL-33 promotes polarization of M2 macrophages and differentiation of Treg cells into Th2 cells and thus attenuates dermal and pulmonary fibrosis through IL-13-dependent fibrotic pathways.<a class="elsevierStyleCrossRefs" href="#bib0965"><span class="elsevierStyleSup">51,52</span></a> The serum level of IL-33 is significantly increased in patients with SSc, especially those with microvascular involvement and skin and pulmonary fibrosis, and is correlated with the severity of pulmonary and skin fibrosis.<a class="elsevierStyleCrossRefs" href="#bib0975"><span class="elsevierStyleSup">53,54</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">B cells</span><p id="par0050" class="elsevierStylePara elsevierViewall">The dysregulation of B cell immunity including hyperactivation of B cells with production of autoantibodies, alteration of B cell homeostasis, and imbalance between B cell subsets, plays a fundamental role in the pathogenesis of SSc.<a class="elsevierStyleCrossRef" href="#bib0985"><span class="elsevierStyleSup">55</span></a> The investigation of lung tissue samples from patients with SSc-ILD has indicated that there are prominent B cell infiltrations in most of the lung specimens in addition to T cell infiltrations.<a class="elsevierStyleCrossRef" href="#bib0990"><span class="elsevierStyleSup">56</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">B regulatory (Breg) cells secrete IL-10, which has potent anti-inflammatory and anti-fibrotic effects, and inhibit CD4<span class="elsevierStyleSup">+</span> T cell proliferation and differentiation of Th1 and Th17 cells.<a class="elsevierStyleCrossRef" href="#bib0995"><span class="elsevierStyleSup">57</span></a> Recent reports have revealed that patients with SSc-ILD have a markedly decreased count of Breg cells compared to patients with SSc but without ILD.<a class="elsevierStyleCrossRefs" href="#bib1000"><span class="elsevierStyleSup">58,59</span></a> Effector B (Beff) cells or activated B cells are responsible for the production of autoantibodies, inducing collagen synthesis of fibroblasts and promoting fibrosis through secretion of IL-6 and TGF-β.<a class="elsevierStyleCrossRef" href="#bib0985"><span class="elsevierStyleSup">55</span></a> A significantly higher level of IL-6-producing Beff cells and decreased level of IL-10-producing Breg cells is observed in patients with SSc compared to healthy controls. There is also a positive correlation between effector B (Beff)/Breg cells ratio and extent of ILD in SSc.<a class="elsevierStyleCrossRef" href="#bib1010"><span class="elsevierStyleSup">60</span></a> In patients with SSc-ILD, a significant increase in serum IL-6 level is detected compared to patients with SSc without ILD, and the level of IL-6 is predictive for deterioration of lung function tests.<a class="elsevierStyleCrossRefs" href="#bib1015"><span class="elsevierStyleSup">61,62</span></a> Another important effect of B cells on SSc is to produce disease-specific autoantibodies such as anti-topoisomerase I autoantibody (ATA) and anti-centromere autoantibody believed to be a contributor to SSc pathogenesis<a class="elsevierStyleCrossRef" href="#bib1025"><span class="elsevierStyleSup">63</span></a> ATA positivity is a strong predictor for the development of ILD in SSc.<a class="elsevierStyleCrossRef" href="#bib1030"><span class="elsevierStyleSup">64</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Fibroblasts–myofibroblasts</span><p id="par0060" class="elsevierStylePara elsevierViewall">Myofibroblasts and fibroblasts are the main driving cells leading to fibrosis through excessive ECM deposition in ILD. Myofibroblasts are derived from various cell types including fibroblasts activated by profibrotic mediators and stimuli, circulating fibrocytes, and mesenchymal transition of epithelial and endothelial cells (EMT and EndoMT).<a class="elsevierStyleCrossRef" href="#bib0915"><span class="elsevierStyleSup">41</span></a> In SSc, cultured fibroblasts derived from BAL have overexpression of myofibroblast phenotype markers such as alpha-smooth muscle cell actin (α-SMA), vimentin, and desmin with increased collagen production.<a class="elsevierStyleCrossRef" href="#bib1035"><span class="elsevierStyleSup">65</span></a></p></span></span></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Screening</span><p id="par0065" class="elsevierStylePara elsevierViewall">Given the devastating consequences of SSc-ILD including its higher mortality rate and negative effects on quality of life, the screening for ILD in SSc has become crucial to early diagnosis and appropriate management.<a class="elsevierStyleCrossRefs" href="#bib0715"><span class="elsevierStyleSup">1,66</span></a> Notwithstanding this imperative, there are still no formal, universally acknowledged screening guidelines for SSc-ILD. Patients with SSc who should be considered for ILD screening are especially those with risk factors for the development of ILD. These risk factors are considered to be dcSSc, presence of anti-topoisomerase I antibody, male sex, African American ethnicity, presence of respiratory symptoms, and history of smoking.<a class="elsevierStyleCrossRef" href="#bib1045"><span class="elsevierStyleSup">67</span></a> Screening for ILD in SSc usually involves careful evaluation of pulmonary symptoms, physical examination, PFTs, and HRCT. All patients with SSc should be examined with lung auscultation, especially for velcro-like crackles, and also respiratory symptoms such as cough and dyspnea should be reviewed to assess the lung involvement at every visit. However, a Canadian research group has shown that the diagnosis of ILD based upon physical examination (presence of basilar velcro-like crackles) and/or chest imaging with radiography has lower sensitivity compared to forced vital capacity (FVC) % predicted in patients with SSc, but higher specificity.</p><p id="par0070" class="elsevierStylePara elsevierViewall">According to expert consensus, PFTs should be ordered in all patients with SSc and repeated regularly.<a class="elsevierStyleCrossRef" href="#bib1045"><span class="elsevierStyleSup">67</span></a> Screening PFTs are usually performed and repeated within six to twelve months. The most commonly assessed PFT parameters are FVC and diffusion capacity of carbon monoxide (DLCO). However, some patients with SSc, particularly those with anti-topoisomerase antibodies, have normal FVC and DLCO values despite the presence of fibrosis on HRCT.<a class="elsevierStyleCrossRef" href="#bib1050"><span class="elsevierStyleSup">68</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">Results of several studies have revealed that these PFT parameters have low sensitivity and specificity for diagnosing ILD in patients with SSc.<a class="elsevierStyleCrossRefs" href="#bib1050"><span class="elsevierStyleSup">68,69</span></a> PFTs also have poor sensitivity for detecting ILD in patients with early diffuse cutaneous systemic sclerosis (dcSSc).<a class="elsevierStyleCrossRef" href="#bib1060"><span class="elsevierStyleSup">70</span></a> However, an EUSTAR report on a very large number of patients has shown that DLCO is the earliest functional parameter to be reduced in SSc-ILD<a class="elsevierStyleCrossRef" href="#bib1065"><span class="elsevierStyleSup">71</span></a> and that it correlated very well with HRCT changes.<a class="elsevierStyleCrossRef" href="#bib1070"><span class="elsevierStyleSup">72</span></a> Taken together, this evidence suggests that the PFTs may raise the suspicion of an ongoing interstitial process but are not sufficient to diagnose ILD in patients with SSc.</p><p id="par0080" class="elsevierStylePara elsevierViewall">HRCT is considered as the gold standard tool for the detection of ILD in SSc.<a class="elsevierStyleCrossRefs" href="#bib1075"><span class="elsevierStyleSup">73,74</span></a> HRCT provides valuable findings including the pattern of ILD and the severity or extent of fibrosis, findings that correlate with disease prognosis.<a class="elsevierStyleCrossRef" href="#bib1085"><span class="elsevierStyleSup">75</span></a> The reports of a survey evaluating the approach of rheumatologists for screening SSc-ILD have revealed that HRCT is used in newly diagnosed patients with SSc by 66% of SSc experts and 51% of general rheumatologists.<a class="elsevierStyleCrossRef" href="#bib1075"><span class="elsevierStyleSup">73</span></a> Another survey analysis has shown that 65% of responders routinely use HRCT as a screening tool for ILD in patients newly diagnosed SSc, and 30.7% of responders perform HRCT when clinical indicators of ILD such as a decline in PFTs (FVC<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>80% predicted), crackles on auscultation or dyspnea are present.<a class="elsevierStyleCrossRef" href="#bib1090"><span class="elsevierStyleSup">76</span></a> A recent prospective study has reported that the majority of patients with SSc undergo HRCT.<a class="elsevierStyleCrossRef" href="#bib1095"><span class="elsevierStyleSup">77</span></a> Use of HRCT is related to the presence of anti-centromere autoantibody and missing FVC values in patients followed at SSc-expert centers.<a class="elsevierStyleCrossRef" href="#bib1095"><span class="elsevierStyleSup">77</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">Expert consensus guidelines recommend that HRCT should be performed in all patients with SSc to screen for ILD.<a class="elsevierStyleCrossRefs" href="#bib1045"><span class="elsevierStyleSup">67,78</span></a> However, there is no consistency in the recommended screening interval with HRCT. Generally, the frequency of obtaining HRCT should be based on the clinician's decision taking into account risk factors for the development of ILD.<a class="elsevierStyleCrossRef" href="#bib1045"><span class="elsevierStyleSup">67</span></a></p><p id="par0090" class="elsevierStylePara elsevierViewall">Recent evidence has suggested that lung ultrasound may be a promising imaging tool for ILD screening because of its high sensitivity to detect parenchymal modifications in SSc.<a class="elsevierStyleCrossRefs" href="#bib1105"><span class="elsevierStyleSup">79–81</span></a> The results of an assessment of ILD in SSc with lung ultrasound have shown an inverse relationship between B-lines and pulmonary function tests and a significant correlation between B-lines and HRCT scores. While currently not widely studied or used for ILD screening, lung ultrasound may emerge as a possible modality for identifying ILD in SSc.<a class="elsevierStyleCrossRef" href="#bib1120"><span class="elsevierStyleSup">82</span></a></p><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">ILD diagnosis in SSc</span><p id="par0095" class="elsevierStylePara elsevierViewall">The clinical course of systemic sclerosis (SSc) is variable. ILD in SSc may be asymptomatic, or present as exertional dyspnea or persistent dry cough.<a class="elsevierStyleCrossRef" href="#bib1125"><span class="elsevierStyleSup">83</span></a> However, dyspnea in SSc may be multifactorial and caused also by vascular disease, musculoskeletal involvement, anemia or cardiac disease.<a class="elsevierStyleCrossRef" href="#bib1130"><span class="elsevierStyleSup">84</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall">Pulmonary complications are the leading cause of disease-related mortality in SSc.<a class="elsevierStyleCrossRef" href="#bib1135"><span class="elsevierStyleSup">85</span></a> ILD was the leading cause of death in a EUSTAR reported cohort of over 5800 patients; 35% of all SSc-related deaths were related to pulmonary fibrosis.<a class="elsevierStyleCrossRef" href="#bib1140"><span class="elsevierStyleSup">86</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">ILD is present in up to 80% of patients with SSc<a class="elsevierStyleCrossRef" href="#bib1145"><span class="elsevierStyleSup">87</span></a> and frequently appears during the first 4–6 years after the disease onset. It is noteworthy that most patients with ILD will develop severe restrictive lung disease in the first 5 years after the onset of symptoms.<a class="elsevierStyleCrossRef" href="#bib1150"><span class="elsevierStyleSup">88</span></a> PFT are neither sensitive nor specific enough to detect early ILD. HRCT is the standard test for confirming the diagnosis.<a class="elsevierStyleCrossRefs" href="#bib1155"><span class="elsevierStyleSup">89–91</span></a> Histological study of the lung is not considered as a routine tool to diagnosis ILD in SSc and is reserved for cases of diagnostic uncertainty.<a class="elsevierStyleCrossRefs" href="#bib1170"><span class="elsevierStyleSup">92,93</span></a></p><p id="par0110" class="elsevierStylePara elsevierViewall">Lung parenchyma involvement in SSc can be due to causes other than ILD and. Patients with SSc-ILD may also have other forms of lung disease as well. Immunosuppressive treatment predisposes to lung infections including COVID19. Carcinoma and pulmonary lymphangitic carcinomatosis can simulate ILD, so that neoplastic processes must be considered in the differential diagnosis of ILD. Other conditions that should be considered in the differential diagnosis of ILD are exposure-related lung disease such as asbestosis, and chronic hypersensitivity pneumonitis.<a class="elsevierStyleCrossRef" href="#bib1180"><span class="elsevierStyleSup">94</span></a></p><p id="par0115" class="elsevierStylePara elsevierViewall">Primary heart involvement or arrhythmia due to SSc can cause left heart dysfunction (LDH) and can also mimic symptoms of ILD. Pulmonary veno-occlusive disease (PVOD) shares some radiological findings with ILD. Transthoracic echocardiography is a useful tool to screen for pulmonary arterial hypertension (PAH) and can help in cases where PAH or left heart disease is suspected.<a class="elsevierStyleCrossRef" href="#bib1185"><span class="elsevierStyleSup">95</span></a></p><p id="par0120" class="elsevierStylePara elsevierViewall">Other pulmonary complications of SSc include the underlying connective tissue disease of the chest wall skin that may directly restrict respiratory movement, and muscle involvement with inflammation or fibrosis that impairs ventilation of the lungs.<a class="elsevierStyleCrossRefs" href="#bib1130"><span class="elsevierStyleSup">84,85</span></a> Pleural disease can occur with pleural effusions, although it is less common than in other CTDs (connective tissue diseases) and may be a clinical indication of an overlap syndrome.</p><p id="par0125" class="elsevierStylePara elsevierViewall">Finally, it is always important to exclude, even if uncommon, the possibility of iatrogenesis caused by immunosuppressive therapy such as acute methotrexate toxicity<a class="elsevierStyleCrossRef" href="#bib1190"><span class="elsevierStyleSup">96</span></a> or amiodarone toxicity.<a class="elsevierStyleCrossRef" href="#bib1195"><span class="elsevierStyleSup">97</span></a></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">ILD classification in SSc</span><p id="par0130" class="elsevierStylePara elsevierViewall">Systemic sclerosis-associated interstitial lung disease (SSc-ILD) can be classified by different ways. It can be categorized by lung-tissue histology, high-resolution computerized tomography (HRCT) imaging-pattern, radiographic extent of disease and likelihood of progression.</p><p id="par0135" class="elsevierStylePara elsevierViewall">The main histological features of SSc-ILD are based on parenchymal infiltration of inflammatory cells and subsequent fibrosis of the lung tissue.<a class="elsevierStyleCrossRefs" href="#bib1200"><span class="elsevierStyleSup">98,99</span></a> The cellular composition of the infiltrates and the disorganization and dysregulation of the lung parenchyma define the different patterns that can be identified. Due to usually good radiologic–histologic pattern correlation, lung biopsy is not usually required.<a class="elsevierStyleCrossRef" href="#bib1175"><span class="elsevierStyleSup">93</span></a> HRCT is usually sufficient confirming ILD and characterizing the type of interstitial changes with a high degree of reliability. Lung biopsy is usually done in cases where malignancy, infection, or other conditions such as hypersensitivity pneumonitis are suspected.</p><p id="par0140" class="elsevierStylePara elsevierViewall">The histological ILD subsets seen in SSc-ILD include non-specific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), organizing pneumonia (OP) and lymphoid interstitial pneumonia (LIP). In SSc-ILD, NSIP is the most common ILD histological pattern, present in up to 77% of cases, although UIP can also be seen in 25–40% of cases.<a class="elsevierStyleCrossRefs" href="#bib1175"><span class="elsevierStyleSup">93,100</span></a></p><p id="par0145" class="elsevierStylePara elsevierViewall">Typically SSc-ILD manifests on HRCT as predominantly ground-class opacities (GGO) with a combination of pulmonary fibrosis, consistent with the NSIP pattern, which can be subcategorized as cellular NSIP or fibrotic NSIP.<a class="elsevierStyleCrossRef" href="#bib1215"><span class="elsevierStyleSup">101</span></a> Fibrotic NSIP is more prevalent than the cellular subtype and has higher risk of progression.<a class="elsevierStyleCrossRef" href="#bib1220"><span class="elsevierStyleSup">102</span></a> However, honeycombing cystic change is reported between 11 and 37% of patients with SSc-ILD.<a class="elsevierStyleCrossRefs" href="#bib1205"><span class="elsevierStyleSup">99,103</span></a> Since the honeycombing pattern is typically a marker for UIP and pulmonary fibrosis and is rarely present in NSIP pattern, it is suggested that patients with SSc-ILD may have an overlap of different patterns. <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> shows the radiological patterns and signs of fibrosis on chest HRCT.<a class="elsevierStyleCrossRef" href="#bib1230"><span class="elsevierStyleSup">104</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0150" class="elsevierStylePara elsevierViewall">Chest HRCT is the main tool to detect and to characterize ILD in SSc. Examples of the NSIP pattern with different radiological signs in patients with SSc are shown in <a class="elsevierStyleCrossRefs" href="#fig0005">Figs. 1–4</a>. As previously noted, it is highly recommended that HRCT be performed in all patients with SSc at the beginning of the disease.<a class="elsevierStyleCrossRef" href="#bib1235"><span class="elsevierStyleSup">105</span></a> HRCT is also useful for the assessment of disease progression. Several studies demonstrated that patients with UIP pattern tend to have worst survival in comparison with patients with NSIP pattern.<a class="elsevierStyleCrossRef" href="#bib1200"><span class="elsevierStyleSup">98</span></a></p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><elsevierMultimedia ident="fig0015"></elsevierMultimedia><elsevierMultimedia ident="fig0020"></elsevierMultimedia></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Prognosis and risk factors</span><p id="par0155" class="elsevierStylePara elsevierViewall">While the ILD pattern on HRCT is useful for diagnosis, and there is a trend for shorter survival in patients with UIP pattern compared to those with an NSIP pattern,<a class="elsevierStyleCrossRef" href="#bib1200"><span class="elsevierStyleSup">98</span></a> the utility of assessing SSc-ILD prognosis on the basis of pattern alone is limited. In contrast, to HRCT patterns, fibrotic findings have been correlated with mortality in SSc. A recent study of the Norwegian nationwide SSc cohort found an association between the presence of fibrosis and mortality.<a class="elsevierStyleCrossRef" href="#bib1160"><span class="elsevierStyleSup">90</span></a> We can find fibrotic features in 55–65% of all patients with SSc and in up to 96% of those with abnormal pulmonary function test (PFT) results.<a class="elsevierStyleCrossRef" href="#bib1205"><span class="elsevierStyleSup">99</span></a></p><p id="par0160" class="elsevierStylePara elsevierViewall">The extent of parenchymal involvement on HRCT is an important outcome measure. Several studies analyzed the visual scoring of lung fibrosis extent and demonstrated that more extensive ILD (>20% of lung tissue involved) was associated with decreased survival.<a class="elsevierStyleCrossRefs" href="#bib1125"><span class="elsevierStyleSup">83,106</span></a> Subsequently, numerous studies have demonstrated a significant correlation between the progression of ILD extent on HRCT scan over time and the decline of predicted DLCO, but only a trend for FVC.<a class="elsevierStyleCrossRefs" href="#bib1245"><span class="elsevierStyleSup">107–109</span></a> However, there is a low degree of agreement on the quantification of the ILD extent among expert radiologists.</p><p id="par0165" class="elsevierStylePara elsevierViewall">Recently, the use of quantitative CT (QCT) methods have been evaluated to improve diagnostic accuracy, and several studies have shown them to be a powerful tool in the evaluation of connective tissue-related ILD and specifically scleroderma-related ILD.<a class="elsevierStyleCrossRef" href="#bib1260"><span class="elsevierStyleSup">110</span></a> Different quantitative analysis tools have shown to produce objective, quantifiable and reproducible assessments of disease progression and stratification. The CALIPER (Computer-Aided Lung Informatics for Pathology Evaluation and Rating) platform is a useful tool not only to quantify lung damage but also to evaluate the worsening of PFTs, as it showed that a value of ground glass<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>4.5% is predictive of DLCO worsening of 10%.<a class="elsevierStyleCrossRef" href="#bib1265"><span class="elsevierStyleSup">111</span></a></p><p id="par0170" class="elsevierStylePara elsevierViewall">The combination of pulmonary fibrosis and emphysema (CPFE syndrome) has been reported in patients with CTD-ILD.<a class="elsevierStyleCrossRefs" href="#bib1270"><span class="elsevierStyleSup">112,113</span></a> A study including a cohort of >300 patients found a significant prevalence of emphysema in patients with SSc-ILD in both smokers and nonsmokers.<a class="elsevierStyleCrossRef" href="#bib1270"><span class="elsevierStyleSup">112</span></a> Emphysema was associated, for a given extent of fibrosis, with a reduction in DLCO of >10%.<a class="elsevierStyleCrossRef" href="#bib1270"><span class="elsevierStyleSup">112</span></a></p><p id="par0175" class="elsevierStylePara elsevierViewall">In SSc-ILD, the clinical course of disease varies widely from slowly progressive, or even stable disease, to severe and rapidly progressing.<a class="elsevierStyleCrossRef" href="#bib1280"><span class="elsevierStyleSup">114</span></a> The prognosis for patients is more closely linked to a combination of severity indicators including progressive functional decline and disease extent of lung fibrosis by HRCT, together with other clinical and laboratory variables.<a class="elsevierStyleCrossRefs" href="#bib1130"><span class="elsevierStyleSup">84,115–117</span></a></p><p id="par0180" class="elsevierStylePara elsevierViewall">Careful prognostic evaluation is essential to the formulation of a management plan, including the staging of disease severity and the definition of longitudinal disease behavior (by serial imaging and PFT).<a class="elsevierStyleCrossRef" href="#bib1135"><span class="elsevierStyleSup">85</span></a></p><p id="par0185" class="elsevierStylePara elsevierViewall">Pulmonary function tests (PFTs) have been associated with an increased risk of mortality <a class="elsevierStyleCrossRefs" href="#bib1300"><span class="elsevierStyleSup">118–120</span></a> in SSc-ILD. A <span class="elsevierStyleItalic">post hoc</span> Cox regression analysis of patients from SLS I and II showed that significant declines in FVC (≥10% predicted) or DLCO (≥15% predicted) over 24 months were strong prognosis factors as predictors of mortality, even when adjusting for treatment arm and baseline disease severity.<a class="elsevierStyleCrossRef" href="#bib1315"><span class="elsevierStyleSup">121</span></a> PFT was added to the to the Outcome Measures in Rheumatology (OMERACT) definition of progression of CTD-ILD. A clinically meaningful progression was defined as: ≥10% relative decline in %FVC predicted or 5–10% relative decline in %FVC and ≥15% relative decline in %DLCO predicted.<a class="elsevierStyleCrossRef" href="#bib1320"><span class="elsevierStyleSup">122</span></a></p><p id="par0190" class="elsevierStylePara elsevierViewall">Additional risk factors for worse prognosis of SSc-ILD include demographic (male sex, older age, African American race, smoking habits) and clinical involvements (absence or presence of respiratory symptoms, arthritis, diffuse SSc subtype with elevated Rodnan skin score, gastro-esophageal reflux disease, pulmonary hypertension), specific antibodies (anti-Scl70 and RNA-polIII) and circulating biomarkers such as elevated C-reactive protein.<a class="elsevierStyleCrossRefs" href="#bib1175"><span class="elsevierStyleSup">93,121–124</span></a> The skin is almost always involved in systemic sclerosis, and several studies have shown that there is an increased risk of ILD and progression of ILD-SSc in presence of diffuse skin involvement.<a class="elsevierStyleCrossRefs" href="#bib1175"><span class="elsevierStyleSup">93,120,125–127</span></a> On the other hand, the presence of anti-centromere antibodies decreases the likelihood to develop ILD.<a class="elsevierStyleCrossRefs" href="#bib1235"><span class="elsevierStyleSup">105,128</span></a></p><p id="par0195" class="elsevierStylePara elsevierViewall">Gastro-esophageal reflux (GERD) is another clinical manifestation recognized as a potential risk impairing lung function in SSc-ILD.<a class="elsevierStyleCrossRefs" href="#bib1355"><span class="elsevierStyleSup">129,130</span></a></p><p id="par0200" class="elsevierStylePara elsevierViewall">Circulating biomarkers have long been associated with the presence and development of SSc-ILD, but their potential to classify ILD and to predict the clinical course of the disease is to date conflicting and their use is not yet validated for management of SSc-ILD in clinical practice.<a class="elsevierStyleCrossRefs" href="#bib1175"><span class="elsevierStyleSup">93,105</span></a> Currently, Krebs von der Lungen-6 serum level (sKL-6) is considered to be one of the most reliable biomarkers for diagnosis, prognosis and prediction of therapeutic responsiveness of SSc-ILD. In SSc-ILD, sKL-6 has been found to be negatively correlated with pulmonary function and positively correlated with radiological extent of lung fibrosis.<a class="elsevierStyleCrossRef" href="#bib1365"><span class="elsevierStyleSup">131</span></a> Furthermore, sKL-6<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>1000<span class="elsevierStyleHsp" style=""></span>U/mL was associated with increased mortality at 5 years of follow-up.<a class="elsevierStyleCrossRef" href="#bib1370"><span class="elsevierStyleSup">132</span></a> The serum values for surfactant protein-A (SP-A) and D (SP-D) have been associated with the extent of damage to the capillary/alveolar barrier, but their diagnostic and prognostic value in SSc-ILD is still controversial.<a class="elsevierStyleCrossRef" href="#bib1375"><span class="elsevierStyleSup">133</span></a> SP-A is known to have lower sensitivity and specificity than SP-D. SP-D appeared to be a strong biomarker for diagnosis.<a class="elsevierStyleCrossRef" href="#bib1365"><span class="elsevierStyleSup">131</span></a> It also is associated with severity of SSc-ILD,<a class="elsevierStyleCrossRef" href="#bib1380"><span class="elsevierStyleSup">134</span></a> correlating significantly with fibrosis scores on HRCT but not with ground-glass opacities.<a class="elsevierStyleCrossRef" href="#bib1365"><span class="elsevierStyleSup">131</span></a> Another promising biomarker for activity and severity of SSc-ILD is the serum level of CCL18 (Pulmonary and Activation Regulated Chemokine (PARC)), which was found to be a predictor of mortality and progression.<a class="elsevierStyleCrossRefs" href="#bib1385"><span class="elsevierStyleSup">135,136</span></a> A large prospective trial with 427 patients with SSc-ILD showed that sCCL18<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>85<span class="elsevierStyleHsp" style=""></span>pg/mL and male sex were the best predictors of functional decline,<a class="elsevierStyleCrossRef" href="#bib1365"><span class="elsevierStyleSup">131</span></a> although the association with mortality was unclear.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Unmet needs and prediction models</span><p id="par0205" class="elsevierStylePara elsevierViewall">Personalized medicine and a multidisciplinary approach are essential to stage the severity of the disease and to determine the likelihood of progression. The current evidence from observational cohorts suggest that only 20–30% of patients with SSc-ILD will develop a progressive disease course.<a class="elsevierStyleCrossRefs" href="#bib1395"><span class="elsevierStyleSup">137–139</span></a> Accurately assessing and defining progression in SSc-ILD could help identify patients at risk. Accordingly, different composite grading systems for screening and prognosis of ILD in SSc have been proposed. Goh et al. developed an algorithm in order to classify patients based on the extent of disease<a class="elsevierStyleCrossRef" href="#bib1125"><span class="elsevierStyleSup">83</span></a> integrating HRCT observations and FVC values from PFTs. Extensive disease was defined as: >20% lung involvement on HRCT or 10–20% lung involvement on HRCT and FVC<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>70% predicted. On the other hand, limited disease was defined as: ≤10% lung involvement on HRCT, or 10–20% lung involvement on HRCT and FVC<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>70% predicted. This prognostic algorithm has been validated as a predictor of mortality. There is an approximately a three-fold increased risk of death and clinical decline (defined as need for supplemental oxygen or lung transplantation) in patients with SSc-ILD how have extensive disease compared to those with limited disease.<a class="elsevierStyleCrossRefs" href="#bib1300"><span class="elsevierStyleSup">118–120</span></a></p><p id="par0210" class="elsevierStylePara elsevierViewall">The SPAR model was suggested in 2018 as a useful composite staging system to predict ILD progression by combining SpO<span class="elsevierStyleInf">2</span> after 6MWT (6-minute walk test) and the presence of arthritis (defined as one or more tender and swollen joints as judged by the treating physician).<a class="elsevierStyleCrossRef" href="#bib1410"><span class="elsevierStyleSup">140</span></a> Wu et al. developed this model by using two independent prospective cohorts of patients who met 2013 ACR/EULAR Classification Criteria for SSc and had mild ILD (<20% lung involvement) assessed by HRCT at baseline. It defined ILD progression as a decrease in FVC<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>15% or ≥10% combined with a decrease in DLCO<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>15% at 1-year follow-up. In their multivariate analysis, declines in SpO<span class="elsevierStyleInf">2</span> after 6MWT and arthritis were identified in both cohorts as independent predictors of ILD progression, with an optimal SpO<span class="elsevierStyleInf">2</span> cut-off value of 94% by receiver–operator characteristic analysis. A latter observational study demonstrated that the SPAR model increased the prediction success rate for ILD progression to 91.7% among patients who fulfilled criteria for both the SpO<span class="elsevierStyleInf">2</span><span class="elsevierStyleHsp" style=""></span>≤<span class="elsevierStyleHsp" style=""></span>94% after 6MWT and arthritis.</p><p id="par0215" class="elsevierStylePara elsevierViewall">Another validated prediction model for mortality risk in SSc-ILD is the smoking history, age, and DLCO (SADL) model, which was developed by using two independent prospective cohorts of patients meeting 2013 ACR/EULAR Criteria for ILD. The three abovementioned variables were included in the final risk prediction model to create a point scoring system used to identify a classification with low, moderate or high mortality risk at Three years from ILD diagnosis.<a class="elsevierStyleCrossRef" href="#bib1415"><span class="elsevierStyleSup">141</span></a></p><p id="par0220" class="elsevierStylePara elsevierViewall">Including simple commonly used variables facilitates the use of these composite-staging systems, which can be useful tools in clinical practice, even though further validation is required.</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Progressive pulmonary fibrosis</span><p id="par0225" class="elsevierStylePara elsevierViewall">Recently, progressive pulmonary fibrosis (PPF), also referred to as progressive fibrosing ILDs (PF-ILD), was recognized as a distinct clinical entity<a class="elsevierStyleCrossRefs" href="#bib1215"><span class="elsevierStyleSup">101,142</span></a> by the American Thoracic Society and European Respiratory Society/ATS/ERS) in collaboration with the American College of Chest Physicians (ACCP). The established definition of PPF is shown in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>.<a class="elsevierStyleCrossRef" href="#bib1215"><span class="elsevierStyleSup">101</span></a></p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0230" class="elsevierStylePara elsevierViewall">Accordingly, PPF is characterized by a disease course like that of idiopathic pulmonary fibrosis (IPF), the prototype of fibrosing ILD, with rapid decline in lung function, respiratory failure, and higher infection risk due to an increased distal alveolar bacterial burden, leading to early mortality. Therefore, it is crucial to monitor the evolution of SSc-ILD, and should rely on multicompartmental assessment (physiological, clinical, and radiological assessment, together with validated biomarkers).</p><p id="par0235" class="elsevierStylePara elsevierViewall">In addition, non-lethal complications of SSc could often be of greater importance to patients than the risk of developing a life-threatening lung manifestation and so a comprehensive, multidisciplinary long-term care plan must provide the context for management of organ-based disease. The recent European consensus statement<a class="elsevierStyleCrossRef" href="#bib1235"><span class="elsevierStyleSup">105</span></a> showed support for a multidimensional model of care and proposed an algorithm to provide clinical guidance for the identification and management of SSc-ILD, assessing ILD severity by using multiple methods (HRCT, FVC and DLCO, exercise-induced blood oxygen desaturation, clinical symptoms, and quality of life).</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Conclusions</span><p id="par0240" class="elsevierStylePara elsevierViewall">In SSc, the early identification of ILD is of paramount importance for prompt initiation of disease management strategies and therapies to slow and hopefully arrest disease evolution. Screening is pivotal and should be regularly conducted early in the SSc disease course in all patients. The gold standard for ILD diagnosis is HRCT, a technique that is associated with radiation exposure and can be burdensome to organize as well as costs. For this reason, the combination of PFTs and lung ultrasound may emerge as a viable approach that can be repeated on multiple occasions without radiation concern. Currently, conclusive diagnosis relies on HRCT with characterization of the architectural features of the lung that also point at the possible pathological pattern. In follow-up, clinical signs and symptoms as well as PFTs and HRCT are instrumental to define disease progression and shape tailored treatment for each SSc patient.</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Conflict of interest</span><p id="par0245" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflict of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres2149717" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1824876" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres2149718" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1824875" "titulo" => "Palabras clave" ] 4 => array:3 [ "identificador" => "sec0005" "titulo" => "The pathogenesis of SSc-related ILD" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0010" "titulo" => "The role of lung/tissue injury in SSc-ILD" ] 1 => array:3 [ "identificador" => "sec0015" "titulo" => "The role of inflammation and alteration of immune cells in SSc-ILD" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "Alveolitis-inflammation" ] 1 => array:2 [ "identificador" => "sec0025" "titulo" => "T cells" ] 2 => array:2 [ "identificador" => "sec0030" "titulo" => "B cells" ] 3 => array:2 [ "identificador" => "sec0035" "titulo" => "Fibroblasts–myofibroblasts" ] ] ] ] ] 5 => array:3 [ "identificador" => "sec0040" "titulo" => "Screening" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0045" "titulo" => "ILD diagnosis in SSc" ] 1 => array:2 [ "identificador" => "sec0050" "titulo" => "ILD classification in SSc" ] ] ] 6 => array:2 [ "identificador" => "sec0055" "titulo" => "Prognosis and risk factors" ] 7 => array:2 [ "identificador" => "sec0060" "titulo" => "Unmet needs and prediction models" ] 8 => array:2 [ "identificador" => "sec0065" "titulo" => "Progressive pulmonary fibrosis" ] 9 => array:2 [ "identificador" => "sec0070" "titulo" => "Conclusions" ] 10 => array:2 [ "identificador" => "sec0075" "titulo" => "Conflict of interest" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2023-05-29" "fechaAceptado" => "2023-07-11" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1824876" "palabras" => array:5 [ 0 => "Systemic sclerosis" 1 => "Interstitial lung disease" 2 => "Lung" 3 => "Treatment" 4 => "Approach" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1824875" "palabras" => array:5 [ 0 => "Esclerosis sistémica" 1 => "Enfermedad intersticial pulmonar" 2 => "Pulmón" 3 => "Tratamiento" 4 => "Abordaje" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Interstitial lung disease (ILD) is a common and potentially devastating complication of systemic sclerosis (SSc), a chronic autoimmune disorder characterized by fibrosis and vascular abnormalities. The association between SSc and ILD underscores the intricate interplay between immune dysregulation, vasculopathy, and tissue fibrosis. This review provides a comprehensive overview of the immunological, clinical, and radiological features of ILD in the context of SSc. It highlights the diverse spectrum of ILD patterns observed in SSc patients, ranging from non-specific interstitial pneumonia to usual interstitial pneumonia. The intricate pathogenic mechanisms linking SSc and ILD involve aberrant immune responses, endothelial dysfunction, profibrotic cytokine signaling, and genetic factors. Immunological alterations, diagnostic challenges, and prognostic implications are discussed, underscoring the need for multidisciplinary management strategies. By elucidating the complex relationship between SSc and ILD, this review aims to contribute to a deeper understanding of the underlying mechanisms and facilitate the development of interdisciplinary interventions for improved patient outcomes.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">La enfermedad pulmonar intersticial (EPI) es una complicación frecuente y potencialmente devastadora de la esclerosis sistémica (SSc), un trastorno autoinmune crónico caracterizado por fibrosis y anomalías vasculares. La asociación entre la SSc y la EPI subraya la difícil interacción entre la desregulación inmunitaria, la vasculopatía y la fibrosis tisular. Esta revisión proporciona una visión global de las características inmunológicas, clínicas y radiológicas de la EPI en el contexto de la SSc; de igual manera, se destaca el diverso espectro de patrones de EPI observados en pacientes con SSc, que van desde la neumonía intersticial inespecífica a la habitual. Los intrincados mecanismos patogénicos que relacionan la SSc y la EPI implican respuestas inmunitarias aberrantes, disfunción endotelial, señalización profibrótica de citoquinas y factores genéticos. Se discuten las alteraciones inmunológicas, los retos diagnósticos y las repercusiones pronósticas, subrayando la necesidad de estrategias de gestión multidisciplinares. Al elucidar la compleja relación entre la SSc y la EPI, esta revisión pretende contribuir a una comprensión más profunda de los mecanismos subyacentes y facilitar el desarrollo de intervenciones interdisciplinarias para mejorar los resultados de los pacientes.</p></span>" ] ] "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "<p id="par00195" class="elsevierStylePara elsevierViewall">The following are the supplementary material to this article:<elsevierMultimedia ident="upi0005"></elsevierMultimedia></p>" "etiqueta" => "Appendix A" "titulo" => "Supplementary material" "identificador" => "sec0085" ] ] ] ] "multimedia" => array:7 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 398 "Ancho" => 905 "Tamanyo" => 79385 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">(A, B) High resolution computed tomography demonstrating NSIP with subpleural ground-glass opacities (short arrows) with traction bronchiectasis (arrows) and sparing of the subpleural lung.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 358 "Ancho" => 1005 "Tamanyo" => 72233 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">(A) NSIP with subpleural multifocal patchy ground-glass opacities (arrows); (B) subpleural dendriform ossification is also observed (arrows).</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 376 "Ancho" => 1005 "Tamanyo" => 107669 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">(A, B) Fibrotic NSIP with subpleural sparing. HRCT shows multifocal patchy ground-glass opacities (short arrows) with traction bronchiectasis (arrows) and sparing of the subpleural lung (black arrows).</p>" ] ] 3 => array:7 [ "identificador" => "fig0020" "etiqueta" => "Fig. 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 547 "Ancho" => 1005 "Tamanyo" => 99981 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">(A) Fibrotic NSIP with lower bilateral ground-glass opacities (arrows) and (B) multiple traction bronchiectasis (arrows).</p>" ] ] 4 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Definition of abbreviations</span>: NSIP<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>non-specific interstitial pneumonia; GGO<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>ground glass opacities; UIP<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>usual interstitial pneumonia; LIP<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>lymphoid interstitial pneumonia; OP<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>organizing pneumonia.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Radiological patterns \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Radiological signs \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NSIP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Peripheral distribution; occasionally central• Preference in inferior lobes• Patchy GGO with linear, reticular, and micronodular images• Traction bronchiectasis/bronchiolectasis when NSIP fibrotic• Infrequent honeycombing cystic pattern \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">UIP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Subpleural, basal and symmetrical; occasionally diffuse• Apico-basal progression• Honeycombing pattern with reticulation, bronchiectasis, and traction bronchiectasis• Minimal ground-glass opacities \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">LIP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Bilateral involvement• Preference in inferior lobes• Patchy areas of GGO with small centrilobular unclearly defined nodules• Multiple thin-walled cysts \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">OP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Peripheral and often frankly subpleural• Patchy areas of consolidation (increased lung attenuation with architectural distortion)• Coalescence progression to diffuse alveolar damage and fibrosis signs with GGO and traction bronchiectasis \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3542875.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Radiological patterns and signs of fibrosis on chest high resolution computed tomography.</p>" ] ] 5 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Definition of abbreviations</span>: ILD<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>interstitial lung disease; IPF<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>idiopathic pulmonary fibrosis; PPF<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>progressive pulmonary fibrosis; Hb<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>hemoglobin.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In a patient with ILD of known or unknown etiology other than IPF who has radiological evidence of pulmonary fibrosis, PFF is defined as at least two of the following three criteria occurring within the past year with no alternative explanation<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>:1. Worsening respiratory symptoms2. Physiological evidence of disease progression (either of the following):<span class="elsevierStyleHsp" style=""></span>a. Absolute decline in FVC<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>5% predicted within 1 year of follow-up<span class="elsevierStyleHsp" style=""></span>b. Absolute decline in DLCO (corrected for Hb)<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>10% predicted within 1 year of follow-up3. Radiological evidence of disease progression (one or more of the following):<span class="elsevierStyleHsp" style=""></span>a. Increased extent or severity of traction bronchiectasis and bronchiolectasis<span class="elsevierStyleHsp" style=""></span>b. New ground-glass opacity with traction bronchiectasis<span class="elsevierStyleHsp" style=""></span>c. New fine reticulation<span class="elsevierStyleHsp" style=""></span>d. Increased extent or increased coarseness of reticular abnormality<span class="elsevierStyleHsp" style=""></span>e. New or increased honeycombing<span class="elsevierStyleHsp" style=""></span>f. Increased lobar volume loss \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3542874.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Although it is critical to exclude alternative explanations of worsening features for all patients with suspected progression, that is particularly important in patients with worsening respiratory symptoms and/or decline in DLCO given the lower specificity of these features for PPF compared with FVC and chest computed tomography.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Definition of progressive pulmonary fibrosis.</p>" ] ] 6 => array:5 [ "identificador" => "upi0005" "tipo" => "MULTIMEDIAECOMPONENTE" "mostrarFloat" => false "mostrarDisplay" => true "Ecomponente" => array:2 [ "fichero" => "mmc1.pdf" "ficheroTamanyo" => 930394 ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:142 [ 0 => array:3 [ "identificador" => "bib0715" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2009.114264" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2010" "volumen" => "69" "paginaInicial" => "1809" "paginaFinal" => "1815" "link" => array:1 [ …1] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0720" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2008.091710" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2009" "volumen" => "68" "paginaInicial" => "961" "paginaFinal" => "965" "link" => array:1 [ …1] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0725" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/acr.21583" "Revista" => array:6 [ "tituloSerie" => "Arthritis Care Res (Hoboken)" "fecha" => "2012" "volumen" => "64" "paginaInicial" => "519" "paginaFinal" => "524" "link" => array:1 [ …1] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0730" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201903-0563CI" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2020" "volumen" => "201" "paginaInicial" => "650" "paginaFinal" => "660" "link" => array:1 [ …1] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0735" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pathogenesis of systemic sclerosis associated interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/2397198320903867" "Revista" => array:7 [ "tituloSerie" => "J Scleroderma Relat Disord" "fecha" => "2020" "volumen" => "5" "numero" => "Suppl." "paginaInicial" => "6" "paginaFinal" => "16" "link" => array:1 [ …1] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0740" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11926-014-0411-1" "Revista" => array:5 [ "tituloSerie" => "Curr Rheumatol Rep" "fecha" => "2014" "volumen" => "16" "paginaInicial" => "411" "link" => array:1 [ …1] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0745" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interstitial lung disease in systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00408-007-9012-3" "Revista" => array:6 [ "tituloSerie" => "Lung" "fecha" => "2007" "volumen" => "185" "paginaInicial" => "211" "paginaFinal" => "220" "link" => array:1 [ …1] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0750" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1165/ajrcmb.10.4.7510986" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Cell Mol Biol" "fecha" => "1994" "volumen" => "10" "paginaInicial" => "405" "paginaFinal" => "412" "link" => array:1 [ …1] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0755" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Coagulation and autoimmunity in scleroderma interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2010.10.002" "Revista" => array:6 [ "tituloSerie" => "Semin Arthritis Rheum" "fecha" => "2011" "volumen" => "41" "paginaInicial" => "212" "paginaFinal" => "222" "link" => array:1 [ …1] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0760" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.24935" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2009" "volumen" => "60" "paginaInicial" => "3455" "paginaFinal" => "3464" "link" => array:1 [ …1] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0765" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.30255" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2011" "volumen" => "63" "paginaInicial" => "1416" "paginaFinal" => "1425" "link" => array:1 [ …1] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0770" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety and tolerability of thrombin inhibition in scleroderma-associated interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/acr2.11049" "Revista" => array:6 [ "tituloSerie" => "ACR Open Rheumatol" "fecha" => "2019" "volumen" => "1" "paginaInicial" => "403" "paginaFinal" => "411" "link" => array:1 [ …1] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0775" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Endothelin and scleroderma lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/ken283" "Revista" => array:7 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2008" "volumen" => "47" "numero" => "Suppl. 5" "paginaInicial" => "v25" "paginaFinal" => "v26" "link" => array:1 [ …1] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0780" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Endothelin-1 secretion by alveolar macrophages in systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/ajrccm.156.5.96-11004" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "1997" "volumen" => "156" "paginaInicial" => "1429" "paginaFinal" => "1435" "link" => array:1 [ …1] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0785" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Stimulation of transforming growth factor-β1-induced endothelial-to-mesenchymal transition and tissue fibrosis by endothelin-1 (ET-1): a novel profibrotic effect of ET-1" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0161988" "Revista" => array:5 [ "tituloSerie" => "PLOS ONE" "fecha" => "2016" "volumen" => "11" "paginaInicial" => "e0161988" "link" => array:1 [ …1] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0790" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Pathol" "fecha" => "1997" "volumen" => "151" "paginaInicial" => "831" "paginaFinal" => "841" "link" => array:1 [ …1] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0795" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Endothelin-1 as a biomarker of idiopathic pulmonary fibrosis and interstitial lung disease associated with autoimmune diseases" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/ijms24021275" "Revista" => array:3 [ "tituloSerie" => "Int J Mol Sci" "fecha" => "2023" "paginaInicial" => "24" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0800" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1165/ajrcmb.11.4.7917311" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Cell Mol Biol" "fecha" => "1994" "volumen" => "11" "paginaInicial" => "439" "paginaFinal" => "445" "link" => array:1 [ …1] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0805" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Circulating endothelin-1 levels in systemic sclerosis subsets – a marker of fibrosis or vascular dysfunction?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "1994" "volumen" => "21" "paginaInicial" => "1838" "paginaFinal" => "1844" "link" => array:1 [ …1] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0810" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Quantitative videocapillaroscopy correlates with functional respiratory parameters: a clue for vasculopathy as a pathogenic mechanism for lung injury in systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s13075-018-1775-9" "Revista" => array:5 [ "tituloSerie" => "Arthritis Res Ther" "fecha" => "2018" "volumen" => "20" "paginaInicial" => "281" "link" => array:1 [ …1] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0815" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Type II alveolar cell. Defender of the alveolus" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/arrd.1977.115.S.81" "Revista" => array:7 [ "tituloSerie" => "Am Rev Respir Dis" "fecha" => "1977" "volumen" => "115" "numero" => "Pt 2" "paginaInicial" => "81" "paginaFinal" => "91" "link" => array:1 [ …1] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0820" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pulmonary involvement in systemic sclerosis: exploring cellular, genetic and epigenetic mechanisms" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00296-020-04658-6" "Revista" => array:6 [ "tituloSerie" => "Rheumatol Int" "fecha" => "2020" "volumen" => "40" "paginaInicial" => "1555" "paginaFinal" => "1569" "link" => array:1 [ …1] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0825" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/kez230" "Revista" => array:6 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2019" "volumen" => "58" "paginaInicial" => "1534" "paginaFinal" => "1546" "link" => array:1 [ …1] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0830" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.bbrc.2005.10.144" "Revista" => array:6 [ "tituloSerie" => "Biochem Biophys Res Commun" "fecha" => "2005" "volumen" => "338" "paginaInicial" => "1845" "paginaFinal" => "1852" "link" => array:1 [ …1] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0835" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/resp.13988" "Revista" => array:6 [ "tituloSerie" => "Respirology" "fecha" => "2021" "volumen" => "26" "paginaInicial" => "461" "paginaFinal" => "468" "link" => array:1 [ …1] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0840" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.rmed.2013.03.015" "Revista" => array:6 [ "tituloSerie" => "Respir Med" "fecha" => "2013" "volumen" => "107" "paginaInicial" => "1079" "paginaFinal" => "1086" "link" => array:1 [ …1] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0845" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1152/ajplung.00163.2007" "Revista" => array:6 [ "tituloSerie" => "Am J Physiol Lung Cell Mol Physiol" "fecha" => "2007" "volumen" => "293" "paginaInicial" => "L525" "paginaFinal" => "L534" "link" => array:1 [ …1] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0850" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2559.1994.tb01293.x" "Revista" => array:6 [ "tituloSerie" => "Histopathology" "fecha" => "1994" "volumen" => "24" "paginaInicial" => "145" "paginaFinal" => "150" "link" => array:1 [ …1] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0855" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Endothelial–mesenchymal transition in bleomycin-induced pulmonary fibrosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1165/rcmb.2009-0031OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Cell Mol Biol" "fecha" => "2010" "volumen" => "43" "paginaInicial" => "161" …2 ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0860" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Endothelial cells expressing endothelial and mesenchymal cell gene products in lung tissue from patients with systemic sclerosis-associated interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.39421" "Revista" => array:6 [ …6] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0865" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201202-0320ST" "Revista" => array:6 [ …6] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0870" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of bronchoalveolar lavage in systemic sclerosis interstitial lung disease: a systematic literature review" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/ph15121584" "Revista" => array:3 [ …3] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0875" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evidence for protein oedema, neutrophil influx, and enhanced collagen production in lungs of patients with systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thx.45.8.606" "Revista" => array:6 [ …6] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0880" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Structural features of interstitial lung disease in systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/ajrccm/144.3_Pt_1.706" "Revista" => array:7 [ …7] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0885" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bronchoalveolar lavage in systemic sclerosis patients: a systematic review" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2174/1573397116666201113091655" "Revista" => array:6 [ …6] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0890" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/ar2766" "Revista" => array:5 [ …5] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0895" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Serum cytokines and their predictive value in pulmonary involvement of systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.36141/svdld.v36i4.7612" "Revista" => array:6 [ …6] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0900" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.11042" "Revista" => array:6 [ …6] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0905" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Fibrotic cytokine interplay in evaluation of disease activity in treatment naïve systemic sclerosis patients from Western India" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0910" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "T cells in systemic sclerosis: a reappraisal" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/kes090" "Revista" => array:6 [ …6] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0915" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cellular interactions in the pathogenesis of interstitial lung diseases" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09059180.00003214" "Revista" => array:6 [ …6] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0920" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IL-13 and IL-33 Serum levels are increased in systemic sclerosis patients with interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3389/fmed.2022.825567" "Revista" => array:5 [ …5] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0925" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/ar3486" "Revista" => array:5 [ …5] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0930" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Serum levels of interleukin 17 and 22 in patients with systemic sclerosis: a single-center cross-sectional study" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00296-022-05250-w" "Revista" => array:6 [ …6] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0935" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Regulatory T cells in systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3389/fimmu.2018.02356" "Revista" => array:5 [ …5] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0940" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Correlation of Th17 cells and CD4<span class="elsevierStyleSup">+</span>CD25<span class="elsevierStyleSup">+</span> regulatory T cells with clinical parameters in patients with systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0945" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Identification of tregs-related genes with molecular patterns in patients with systemic sclerosis related to ILD" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/biom13030535" "Revista" => array:3 [ …3] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0950" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Higher levels of serum interleukin-35 are associated with the severity of pulmonary fibrosis and Th2 responses in patients with systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00296-018-4071-8" "Revista" => array:6 [ …6] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0955" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0005981" "Revista" => array:5 [ …5] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0960" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Increased proportions of functionally impaired regulatory T cell subsets in systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clim.2017.05.013" "Revista" => array:6 [ …6] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0965" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Role of interleukin-13 in fibrosis, particularly systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/biof.1117" "Revista" => array:6 [ …6] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0970" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The association of IL-33 and systemic sclerosis: a systematic review and meta-analysis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12026-022-09329-1" "Revista" => array:6 [ …6] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0975" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IL33 and sST2 serum level in systemic sclerosis microvascular involvement" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.mvr.2022.104344" "Revista" => array:5 [ …5] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0980" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10067-011-1686-5" "Revista" => array:6 [ …6] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0985" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dysregulated B cell function and disease pathogenesis in systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3389/fimmu.2022.999008" "Revista" => array:5 [ …5] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0990" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "B cell infiltration in systemic sclerosis-associated interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.22847" "Revista" => array:6 [ …6] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0995" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/eji.201040673" "Revista" => array:6 [ …6] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib1000" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/kev331" "Revista" => array:6 [ …6] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib1005" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.39437" "Revista" => array:6 [ …6] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib1010" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cytokine-producing B-cell balance associates with skin fibrosis in patients with systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/1346-8138.16495" "Revista" => array:6 [ …6] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib1015" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Peripheral blood IL-6 levels in systemic sclerosis patients: correlation between IL-6 levels and clinical phenotypes" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jocd.15133" "Revista" => array:6 [ …6] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib1020" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.120725" "Revista" => array:6 [ …6] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib1025" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "B-cells in systemic sclerosis: emerging evidence from genetics to phenotypes" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/BOR.0000000000000215" "Revista" => array:6 [ …6] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib1030" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic sclerosis-specific antibodies: novel and classical biomarkers" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12016-022-08946-w" "Revista" => array:6 [ …6] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib1035" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Growth and characterization of fibroblasts obtained from bronchoalveolar lavage of patients with scleroderma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib1040" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/keac325" "Revista" => array:6 [ …6] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib1045" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2665-9913(19)30144-4" "Revista" => array:6 [ …6] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib1050" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Performance of forced vital capacity and lung diffusion cutpoints for associated radiographic interstitial lung disease in systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.171362" "Revista" => array:6 [ …6] ] ] ] ] ] 68 => array:3 [ "identificador" => "bib1055" "etiqueta" => "69" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.39405" "Revista" => array:6 [ …6] ] ] ] ] ] 69 => array:3 [ "identificador" => "bib1060" "etiqueta" => "70" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Performance characteristics of pulmonary function tests for the detection of interstitial lung disease in adults with early diffuse cutaneous systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.41415" "Revista" => array:6 [ …6] ] ] ] ] ] 70 => array:3 [ "identificador" => "bib1065" "etiqueta" => "71" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0163894" "Revista" => array:5 [ …5] ] ] ] ] ] 71 => array:3 [ "identificador" => "bib1070" "etiqueta" => "72" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2014-206076" "Revista" => array:6 [ …6] ] ] ] ] ] 72 => array:3 [ "identificador" => "bib1075" "etiqueta" => "73" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Screening high-resolution computed tomography of the chest to detect interstitial lung disease in systemic sclerosis: a global survey of rheumatologists" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.40441" "Revista" => array:6 [ …6] ] ] ] ] ] 73 => array:3 [ "identificador" => "bib1080" "etiqueta" => "74" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.41933" "Revista" => array:6 [ …6] ] ] ] ] ] 74 => array:3 [ "identificador" => "bib1085" "etiqueta" => "75" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of systemic sclerosis-associated interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/BOR.0000000000000592" "Revista" => array:6 [ …6] ] ] ] ] ] 75 => array:3 [ "identificador" => "bib1090" "etiqueta" => "76" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High-resolution computed tomography of the chest for the screening, re-screening and follow-up of systemic sclerosis-associated interstitial lung disease: a EUSTAR-SCTC survey" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.55563/clinexprheumatol/7ry6zz" "Revista" => array:6 [ …6] ] ] ] ] ] 76 => array:3 [ "identificador" => "bib1095" "etiqueta" => "77" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Computed tomography of the chest to screen for interstitial lung disease in patients with systemic sclerosis at expert scleroderma centers in the United States" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/acr2.11434" "Revista" => array:6 [ …6] ] ] ] ] ] 77 => array:3 [ "identificador" => "bib1100" "etiqueta" => "78" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Expert consensus on the management of systemic sclerosis-associated interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s12931-022-02292-3" "Revista" => array:5 [ …5] ] ] ] ] ] 78 => array:3 [ "identificador" => "bib1105" "etiqueta" => "79" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of lung ultrasound in systemic sclerosis: a systematic review" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/RHU.0000000000001947" "Revista" => array:6 [ …6] ] ] ] ] ] 79 => array:3 [ "identificador" => "bib1110" "etiqueta" => "80" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pulmonary ultrasonography in systemic sclerosis-induced interstitial lung disease – a systematic review and meta-analysis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/diagnostics13081429" "Revista" => array:3 [ …3] ] ] ] ] ] 80 => array:3 [ "identificador" => "bib1115" "etiqueta" => "81" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Development and assessment of novel lung ultrasound interpretation criteria for the detection of interstitial lung disease in systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/acr.24338" "Revista" => array:6 [ …6] ] ] ] ] ] 81 => array:3 [ "identificador" => "bib1120" "etiqueta" => "82" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lung ultrasound B-lines in systemic sclerosis: cut-off values and methodological indications for interstitial lung disease screening" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/keab801" "Revista" => array:7 [ …7] ] ] ] ] ] 82 => array:3 [ "identificador" => "bib1125" "etiqueta" => "83" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interstitial lung disease in systemic sclerosis: a simple staging system" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200706-877OC" "Revista" => array:6 [ …6] ] ] ] ] ] 83 => array:3 [ "identificador" => "bib1130" "etiqueta" => "84" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Major lung complications of systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41584-018-0062-0" "Revista" => array:6 [ …6] ] ] ] ] ] 84 => array:3 [ "identificador" => "bib1135" "etiqueta" => "85" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/978-1-4419-5774-0" "Libro" => array:4 [ …4] ] ] ] ] ] 85 => array:3 [ "identificador" => "bib1140" "etiqueta" => "86" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2009.114264" "Revista" => array:6 [ …6] ] ] ] ] ] 86 => array:3 [ "identificador" => "bib1145" "etiqueta" => "87" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s13075-015-0872-2" "Revista" => array:6 [ …6] ] ] ] ] ] 87 => array:3 [ "identificador" => "bib1150" "etiqueta" => "88" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(17)30933-9" "Revista" => array:6 [ …6] ] ] ] ] ] 88 => array:3 [ "identificador" => "bib1155" "etiqueta" => "89" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.39405" "Revista" => array:6 [ …6] ] ] ] ] ] 89 => array:3 [ "identificador" => "bib1160" "etiqueta" => "90" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201903-0486OC" "Revista" => array:6 [ …6] ] ] ] ] ] 90 => array:3 [ "identificador" => "bib1165" "etiqueta" => "91" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interstitial lung disease in systemic sclerosis: progress in screening and early diagnosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/BOR.0000000000000323" "Revista" => array:6 [ …6] ] ] ] ] ] 91 => array:3 [ "identificador" => "bib1170" "etiqueta" => "92" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Spectrum of fibrotic lung diseases" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMra2005230" "Revista" => array:6 [ …6] ] ] ] ] ] 92 => array:3 [ "identificador" => "bib1175" "etiqueta" => "93" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of progressive pulmonary fibrosis associated with connective tissue disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/17476348.2022.2107508" "Revista" => array:6 [ …6] ] ] ] ] ] 93 => array:3 [ "identificador" => "bib1180" "etiqueta" => "94" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis of idiopathic pulmonary fibrosis: differential diagnosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/medsci6030073" "Revista" => array:4 [ …4] ] ] ] ] ] 94 => array:3 [ "identificador" => "bib1185" "etiqueta" => "95" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Survival in systemic sclerosis-pulmonary arterial hypertension assessment and recognition of outcomes in scleroderma (PHAROS) registry" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2015.06.011" "Revista" => array:6 [ …6] ] ] ] ] ] 95 => array:3 [ "identificador" => "bib1190" "etiqueta" => "96" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Methotrexate and rheumatoid arthritis associated interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/13993003.00337-2020" "Revista" => array:5 [ …5] ] ] ] ] ] 96 => array:3 [ "identificador" => "bib1195" "etiqueta" => "97" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I)" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1378/chest.93.5.1067" "Revista" => array:6 [ …6] ] ] ] ] ] 97 => array:3 [ "identificador" => "bib1200" "etiqueta" => "98" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1378/chest.08-0053" "Revista" => array:6 [ …6] ] ] ] ] ] 98 => array:3 [ "identificador" => "bib1205" "etiqueta" => "99" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1378/chest.07-2444" "Revista" => array:6 [ …6] ] ] ] ] ] 99 => array:3 [ "identificador" => "bib1210" "etiqueta" => "100" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interstitial lung disease in scleroderma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.rdc.2014.12.005" "Revista" => array:6 [ …6] ] ] ] ] ] 100 => array:3 [ "identificador" => "bib1215" "etiqueta" => "101" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.202202-0399ST" "Revista" => array:6 [ …6] ] ] ] ] ] 101 => array:3 [ "identificador" => "bib1220" "etiqueta" => "102" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Progressive fibrosing interstitial lung disease a proposed integrated algorithm for management" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1513/AnnalsATS.202003-214PS" "Revista" => array:6 [ …6] ] ] ] ] ] 102 => array:3 [ "identificador" => "bib1225" "etiqueta" => "103" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.2106012" "Revista" => array:6 [ …6] ] ] ] ] ] 103 => array:3 [ "identificador" => "bib1230" "etiqueta" => "104" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Basic HRCT patterns in diffuse interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.rx.2022.10.003" "Revista" => array:6 [ …6] ] ] ] ] ] 104 => array:3 [ "identificador" => "bib1235" "etiqueta" => "105" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2665-9913(19)30144-4" "Revista" => array:6 [ …6] ] ] ] ] ] 105 => array:3 [ "identificador" => "bib1240" "etiqueta" => "106" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/kes289" "Revista" => array:5 [ …5] ] ] ] ] ] 106 => array:3 [ "identificador" => "bib1245" "etiqueta" => "107" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prognostic factors for lung function in systemic sclerosis: Prospective study of 105 cases" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00060209" "Revista" => array:6 [ …6] ] ] ] ] ] 107 => array:3 [ "identificador" => "bib1250" "etiqueta" => "108" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Correlation of delta high-resolution computed tomography (HRCT) score with delta clinical variables in early systemic sclerosis (SSc) patients" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.21037/qims.2016.08.08" "Revista" => array:6 [ …6] ] ] ] ] ] 108 => array:3 [ "identificador" => "bib1255" "etiqueta" => "109" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evolution of high-resolution CT-scan in systemic sclerosis-associated interstitial lung disease: description and prognosis factors" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2020.02.015" "Revista" => array:6 [ …6] ] ] ] ] ] 109 => array:3 [ "identificador" => "bib1260" "etiqueta" => "110" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Quantitative CT analysis of diffuse lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1148/rg.2020190099" "Revista" => array:6 [ …6] ] ] ] ] ] 110 => array:3 [ "identificador" => "bib1265" "etiqueta" => "111" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Assessment of interstitial lung disease in systemic sclerosis using the quantitative CT algorithm CALIPER" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10067-020-04938-3" "Revista" => array:6 [ …6] ] ] ] ] ] 111 => array:3 [ "identificador" => "bib1270" "etiqueta" => "112" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Combined pulmonary fibrosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.39528" "Revista" => array:6 [ …6] ] ] ] ] ] 112 => array:3 [ "identificador" => "bib1275" "etiqueta" => "113" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.30077" "Revista" => array:5 [ …5] ] ] ] ] ] 113 => array:3 [ "identificador" => "bib1280" "etiqueta" => "114" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Natural history of systemic sclerosis-related interstitial lung disease: how to identify a progressive fibrosing phenotype" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/2397198319889549" "Revista" => array:2 [ …2] ] ] ] ] ] 114 => array:3 [ "identificador" => "bib1285" "etiqueta" => "115" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interstitial lung disease associated with systemic sclerosis (SSc-ILD)" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s12931-019-0980-7" "Revista" => array:3 [ …3] ] ] ] ] ] 115 => array:3 [ "identificador" => "bib1290" "etiqueta" => "116" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Personalized medicine in systemic sclerosis: facts and promises" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11926-014-0425-8" "Revista" => array:3 [ …3] ] ] ] ] ] 116 => array:3 [ "identificador" => "bib1295" "etiqueta" => "117" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/BOR.0000000000000741" "Revista" => array:6 [ …6] ] ] ] ] ] 117 => array:3 [ "identificador" => "bib1300" "etiqueta" => "118" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predictors of end stage lung disease in a cohort of patients with scleroderma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.62.2.146" "Revista" => array:6 [ …6] ] ] ] ] ] 118 => array:3 [ "identificador" => "bib1305" "etiqueta" => "119" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predictors of fatigue severity in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0026061" "Revista" => array:4 [ …4] ] ] ] ] ] 119 => array:3 [ "identificador" => "bib1310" "etiqueta" => "120" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prediction of pulmonary complications and long-term survival in systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.38390" "Revista" => array:6 [ …6] ] ] ] ] ] 120 => array:3 [ "identificador" => "bib1315" "etiqueta" => "121" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2018-213708" "Revista" => array:5 [ …5] ] ] ] ] ] 121 => array:3 [ "identificador" => "bib1320" "etiqueta" => "122" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Connective tissue disease-associated interstitial lung diseases (CTD-ILD) – report from OMERACT CTD-ILD Working Group" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.141182" "Revista" => array:6 [ …6] ] ] ] ] ] 122 => array:3 [ "identificador" => "bib1325" "etiqueta" => "123" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/acr.21968" "Revista" => array:5 [ …5] ] ] ] ] ] 123 => array:3 [ "identificador" => "bib1330" "etiqueta" => "124" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European scleroderma trials and research (Eustar) cohort" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2018-213455" "Revista" => array:6 [ …6] ] ] ] ] ] 124 => array:3 [ "identificador" => "bib1335" "etiqueta" => "125" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s13075-016-0993-2" "Revista" => array:6 [ …6] ] ] ] ] ] 125 => array:3 [ "identificador" => "bib1340" "etiqueta" => "126" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00296-017-3916-x" "Revista" => array:6 [ …6] ] ] ] ] ] 126 => array:3 [ "identificador" => "bib1345" "etiqueta" => "127" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predictors of progression in systemic sclerosis patients with interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/13993003.02026-2019" "Revista" => array:3 [ …3] ] ] ] ] ] 127 => array:3 [ "identificador" => "bib1350" "etiqueta" => "128" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 128 => array:3 [ "identificador" => "bib1355" "etiqueta" => "129" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Gastro-oesophageal reflux and aspiration in patients with advanced lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thx.2007.082719" "Revista" => array:6 [ …6] ] ] ] ] ] 129 => array:3 [ "identificador" => "bib1360" "etiqueta" => "130" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interstitial lung disease in systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 130 => array:3 [ "identificador" => "bib1365" "etiqueta" => "131" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Performance of Candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.40815" "Revista" => array:6 [ …6] ] ] ] ] ] 131 => array:3 [ "identificador" => "bib1370" "etiqueta" => "132" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2796.2006.01704.x" "Revista" => array:6 [ …6] ] ] ] ] ] 132 => array:3 [ "identificador" => "bib1375" "etiqueta" => "133" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Potential biomarkers in systemic sclerosis: a literature review and update" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/jcm9113388" "Revista" => array:6 [ …6] ] ] ] ] ] 133 => array:3 [ "identificador" => "bib1380" "etiqueta" => "134" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/1529-0131(200106)44:6<1363::AID-ART229>3.0.CO;2-5" "Revista" => array:5 [ …5] ] ] ] ] ] 134 => array:3 [ "identificador" => "bib1385" "etiqueta" => "135" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00004711" "Revista" => array:6 [ …6] ] ] ] ] ] 135 => array:3 [ "identificador" => "bib1390" "etiqueta" => "136" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00131713" "Revista" => array:6 [ …6] ] ] ] ] ] 136 => array:3 [ "identificador" => "bib1395" "etiqueta" => "137" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.40130" "Revista" => array:6 [ …6] ] ] ] ] ] 137 => array:3 [ "identificador" => "bib1400" "etiqueta" => "138" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2020-217455" "Revista" => array:6 [ …6] ] ] ] ] ] 138 => array:3 [ "identificador" => "bib1405" "etiqueta" => "139" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Natural variability in the disease course of SSC-ILD: implications for treatment" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/16000617.0340-2020" "Revista" => array:3 [ …3] ] ] ] ] ] 139 => array:3 [ "identificador" => "bib1410" "etiqueta" => "140" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2018-213201" "Revista" => array:6 [ …6] ] ] ] ] ] 140 => array:3 [ "identificador" => "bib1415" "etiqueta" => "141" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mortality risk prediction in scleroderma-related interstitial lung disease: the SADL model" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.chest.2017.06.009" "Revista" => array:6 [ …6] ] ] ] ] ] 141 => array:3 [ "identificador" => "bib1420" "etiqueta" => "142" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Progressive pulmonary fibrosis: all roads lead to Rome (but not all at the same speed)" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/13993003.01449-2022" "Revista" => array:3 [ …3] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/01218123/00000031000000S1/v5_202405200140/S0121812323000695/v5_202405200140/en/main.assets" "Apartado" => array:4 [ "identificador" => "95645" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Review articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/01218123/00000031000000S1/v5_202405200140/S0121812323000695/v5_202405200140/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0121812323000695?idApp=UINPBA00004N" ]
